Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.68 |
| ▸ | GSK3B | P49841 | 9/20 | 0.68 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.68 |
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | FOS | P01100 | 1/20 | 0.50 |
| ▸ | JUN | P05412 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12291332 | 0.90 | FOS (0.67) | BACE1GSK3BTLR9MMP2MMP9 | |
| SCHEMBL15249303 | 0.88 | MMP2 (0.51) | BACE1GSK3BTLR9MMP2MMP9 | |
| SCHEMBL12291330 | 0.87 | BACE1 (0.53) | BACE1GSK3BTLR9MMP2MMP9 | |
| SCHEMBL13358511 | 0.86 | GSK3B (0.69) | BACE1GSK3BTLR9MMP2MMP9 | |
| SCHEMBL17691402 | 0.86 | MMP2 (0.52) | BACE1GSK3BTLR9MMP2MMP9 | |
| SCHEMBL26555396 | 0.86 | BACE1 (0.48) | BACE1GSK3BTLR9MMP2MMP9 | |
| SCHEMBL4544307 | 0.84 | MMP2 (0.74) | BACE1GSK3BTLR9TYRMMP2 | |
| SCHEMBL13446382 | 0.84 | MMP2 (0.74) | BACE1GSK3BTLR9TYRMMP2 | |
| SCHEMBL11928819 | 0.84 | MMP2 (0.74) | BACE1GSK3BTLR9TYRMMP2 | |
| SCHEMBL15042796 | 0.83 | MMP2 (0.55) | BACE1GSK3BTLR9MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839637-B2 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2023-12-12 | — | — | US | disclosed |
| US-20230190856-A1 | COMPOSITION COMPRISING A COMPLEX COMPRISING A CURCUMINOID COMPOUND, AND STEVIOL GLYCOSIDES OR A LICORICE EXTRACT OR A FRACTION THEREOF, AND USES THEREOF | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20140248382-A1 | CURCUMINOID-BASED COMPOUND/STEVIOSIDE-CONTAINING COMPLEX FOR THE PREVENTION AND TREATMENT OF AN INFLUENZA VIRUS INFECTION | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-09-04 | — | — | US | disclosed |
| US-8545903-B2 | Composition for the prevention and treatment of influenza virus infection and composition for suppressing neuraminidase activity comprising turmeric extract | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-10-01 | — | — | US | disclosed |
| US-20120107429-A1 | Composition For The Prevention And Treatment Of Influenza Virus Infection And Composition For Suppressing Neuraminidase Activity Comprising Turmeric Extract | BIOTEN CO., LTD. (KR) | 2012-05-03 | — | — | US | disclosed |
| EP-1494993-B1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | UNIV NORTH CAROLINA (US) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190856-A1 | COMPOSITION COMPRISING A COMPLEX COMPRISING A CURCUMINOID COMPOUND, AND STEVIOL GLYCOSIDES OR A LICORICE EXTRACT OR A FRACTION THEREOF, AND USES THEREOF | CD4, IFNG, CD14 | BACE1 1151/4885GSK3B 1132/4885TLR9 177/4885 |
| US-20140248382-A1 | CURCUMINOID-BASED COMPOUND/STEVIOSIDE-CONTAINING COMPLEX FOR THE PREVENTION AND TREATMENT OF AN INFLUENZA VIRUS INFECTION | VIP, CRY1, MAVS | BACE1 83/4885GSK3B 1759/4885TLR9 1604/4885 |
| US-20120107429-A1 | Composition For The Prevention And Treatment Of Influenza Virus Infection And Composition For Suppressing Neuraminidase Activity Comprising Turmeric Extract | NEU1, NEU3, NEU4 | BACE1 88/4885GSK3B 1413/4885TLR9 3152/4885 |
| US-11839637-B2 | Neuron activator | BDNF, DBH, CHAT | BACE1 92/4885GSK3B 2892/4885TLR9 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.